You have 9 free searches left this month | for more free features.

CD38-CART

Showing 1 - 25 of 4,392

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial (3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Multiple Myeloma (MM)
  • 3x10(6) CART-38 cellls
  • +5 more
  • (no location specified)
Jul 15, 2022

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Evan Syndrome
  • Treatment
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023

Acquired Hemophilia Trial in Tianjin (Daratumumab)

Recruiting
  • Acquired Hemophilia
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023

Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Antiphospholipid Syndrome
  • Thrombocytopenia
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

Acute Myeloid Leukemia Trial in Suzhou (CART-38)

Recruiting
  • Acute Myeloid Leukemia
  • CART-38
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 21, 2020

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)

Not yet recruiting
  • Antibody-mediated Rejection
  • Kidney Tranplant
  • Hangzhou, Zhejiang, China
    79# Qingchun Road
Jun 21, 2023

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

Advanced Solid Tumor Trial in New York (STI-6129)

Not yet recruiting
  • Advanced Solid Tumor
  • STI-6129
  • New York, New York
    Columbia University Medical Center
Jan 26, 2023

Light Chain (AL) Amyloidosis Trial (STI-6129)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • (no location specified)
Jan 11, 2023

Study for Patients Treat With WU-CART-007

Enrolling by invitation
  • T-cell Acute Lymphoblastic Leukemia
  • T-cell Lymphoblastic Lymphoma
  • Genetic: WU-CART-007
  • Saint Louis, Missouri
    Washington University
Aug 18, 2022

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

Not yet recruiting
  • Nephrotic Syndrome
  • Genova, Italy
    IRCCS G. Gaslini
Jan 19, 2023

Multiple Myeloma Trial in Irvine (89Zr-daratumumab PET/CT)

Recruiting
  • Multiple Myeloma
  • 89Zr-daratumumab PET/CT
  • Irvine, California
    Hoag Memorial Hospital Presbyterian
Aug 1, 2022

Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
Jan 17, 2023

AML Trial in Hangzhou (CD38 CAR T-cells)

Recruiting
  • AML
  • CD38 CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 13, 2022

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Recruiting
  • Acute Myeloid Leukemia
  • CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Relapsed or Refractory Multiple Myeloma Trial in United States (CAR2 Anti-CD38 A2 CAR-T Cells)

Completed
  • Relapsed or Refractory Multiple Myeloma
  • CAR2 Anti-CD38 A2 CAR-T Cells
  • Jacksonville, Florida
  • +3 more
Mar 14, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-cell Non Hodgkin Lymphoma
  • CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
  • Aurora, Colorado
    Children's Hospital Colorado
Nov 9, 2022